Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 31, 2013 Filed Nov 4, 2013 20:55 UTC |
READ IAN CDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 158 | $30.69 | $4,849.02 |
DisclosureSEC source: 0001225208-13-022776 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,351 Underlying: Common Stock · 158 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 31, 2013 Filed Nov 4, 2013 20:55 UTC |
OLSON LAURIE JExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 32 | $30.69 | $982.08 |
DisclosureSEC source: 0001225208-13-022777 · doc4.xml · derivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 563 Underlying: Common Stock · 32 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 31, 2013 Filed Nov 4, 2013 20:55 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 35 | $30.69 | $1,074.15 |
DisclosureSEC source: 0001225208-13-022778 · doc4.xml · derivative · entry 1 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,653 Underlying: Common Stock · 35 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 31, 2013 Filed Nov 4, 2013 20:55 UTC |
HILL CHARLES HExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 42 | $30.69 | $1,288.98 |
DisclosureSEC source: 0001225208-13-022779 · doc4.xml · derivative · entry 1 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,531 Underlying: Common Stock · 42 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 31, 2013 Filed Nov 4, 2013 20:55 UTC |
Germano Geno JBusiness Unit President
|
GrantPhantom Stock Units SSP · Derivative | 49 | $30.69 | $1,503.81 |
DisclosureSEC source: 0001225208-13-022780 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,143 Underlying: Common Stock · 49 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 31, 2013 Filed Nov 4, 2013 20:55 UTC |
Dolsten MikaelPresident R&D
|
GrantPhantom Stock Units SSP · Derivative | 68 | $30.69 | $2,086.92 |
DisclosureSEC source: 0001225208-13-022781 · doc4.xml · derivative · entry 1 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,097 Underlying: Common Stock · 68 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 31, 2013 Filed Nov 4, 2013 20:55 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 61 | $30.69 | $1,872.09 |
DisclosureSEC source: 0001225208-13-022782 · doc4.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,236 Underlying: Common Stock · 61 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 31, 2013 Filed Nov 4, 2013 20:55 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
GrantPhantom Stock Units SSP · Derivative | 51 | $30.69 | $1,565.19 |
DisclosureSEC source: 0001225208-13-022783 · doc4.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,166 Underlying: Common Stock · 51 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 31, 2013 Filed Nov 4, 2013 20:56 UTC |
MADDALUNA ANTHONY JExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 187 | $30.69 | $5,739.03 |
DisclosureSEC source: 0001225208-13-022787 · doc4.xml · derivative · entry 6 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,478 Underlying: Common Stock · 187 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 31, 2013 Filed Nov 4, 2013 20:59 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantPhantom Stock Units SSP · Derivative | 30 | $30.69 | $920.70 |
DisclosureSEC source: 0001225208-13-022790 · doc4.xml · derivative · entry 4 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,548 Underlying: Common Stock · 30 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 28, 2013 Filed Oct 29, 2013 21:44 UTC |
READ IAN CDirector · Chairman & CEO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 193,000 | $0.00 Strike: $26.20 | $0.00 |
DisclosureSEC source: 0001225208-13-022415 · doc4.xml · derivative · entry 19 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 193,000 shares Expires 2016-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2013 Filed Oct 29, 2013 21:44 UTC |
READ IAN CDirector · Chairman & CEO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 145,000 | $0.00 Strike: $26.20 | $0.00 |
DisclosureSEC source: 0001225208-13-022415 · doc4.xml · derivative · entry 18 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 145,000 shares Expires 2015-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options are fully exercisable. Read SEC document |
| October 28, 2013 Filed Oct 29, 2013 21:44 UTC |
READ IAN CDirector · Chairman & CEO
|
SaleCommon Stock | 52,000 | $30.60 | $1,591,200.00 |
DisclosureSEC source: 0001225208-13-022415 · doc4.xml · nonDerivative · entry 15 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,074,267 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2013. Read SEC document |
| October 28, 2013 Filed Oct 29, 2013 21:44 UTC |
READ IAN CDirector · Chairman & CEO
|
SaleCommon Stock | 40,100 | $30.51 | $1,223,451.00 |
DisclosureSEC source: 0001225208-13-022415 · doc4.xml · nonDerivative · entry 14 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,126,267 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2013. Read SEC document |
| October 28, 2013 Filed Oct 29, 2013 21:44 UTC |
READ IAN CDirector · Chairman & CEO
|
SaleCommon Stock | 39,900 | $30.56 | $1,219,344.00 |
DisclosureSEC source: 0001225208-13-022415 · doc4.xml · nonDerivative · entry 13 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,166,367 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2013. Read SEC document |
| October 28, 2013 Filed Oct 29, 2013 21:44 UTC |
READ IAN CDirector · Chairman & CEO
|
SaleCommon Stock | 37,734 | $30.55 | $1,152,773.70 |
DisclosureSEC source: 0001225208-13-022415 · doc4.xml · nonDerivative · entry 12 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,206,267 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2013. Read SEC document |
| October 28, 2013 Filed Oct 29, 2013 21:44 UTC |
READ IAN CDirector · Chairman & CEO
|
SaleCommon Stock | 36,591 | $30.62 | $1,120,416.42 |
DisclosureSEC source: 0001225208-13-022415 · doc4.xml · nonDerivative · entry 11 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,244,001 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2013. Read SEC document |
| October 28, 2013 Filed Oct 29, 2013 21:44 UTC |
READ IAN CDirector · Chairman & CEO
|
SaleCommon Stock | 30,320 | $30.52 | $925,366.40 |
DisclosureSEC source: 0001225208-13-022415 · doc4.xml · nonDerivative · entry 10 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,280,592 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2013. Read SEC document |
| October 28, 2013 Filed Oct 29, 2013 21:44 UTC |
READ IAN CDirector · Chairman & CEO
|
SaleCommon Stock | 27,400 | $30.59 | $838,166.00 |
DisclosureSEC source: 0001225208-13-022415 · doc4.xml · nonDerivative · entry 9 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,310,912 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2013. Read SEC document |
| October 28, 2013 Filed Oct 29, 2013 21:44 UTC |
READ IAN CDirector · Chairman & CEO
|
SaleCommon Stock | 18,700 | $30.50 | $570,350.00 |
DisclosureSEC source: 0001225208-13-022415 · doc4.xml · nonDerivative · entry 8 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,338,312 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2013. Read SEC document |
| October 28, 2013 Filed Oct 29, 2013 21:44 UTC |
READ IAN CDirector · Chairman & CEO
|
SaleCommon Stock | 18,060 | $30.63 | $553,177.80 |
DisclosureSEC source: 0001225208-13-022415 · doc4.xml · nonDerivative · entry 7 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,357,012 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2013. Read SEC document |
| October 28, 2013 Filed Oct 29, 2013 21:44 UTC |
READ IAN CDirector · Chairman & CEO
|
SaleCommon Stock | 12,415 | $30.61 | $380,023.15 |
DisclosureSEC source: 0001225208-13-022415 · doc4.xml · nonDerivative · entry 6 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,375,072 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2013. Read SEC document |
| October 28, 2013 Filed Oct 29, 2013 21:44 UTC |
READ IAN CDirector · Chairman & CEO
|
SaleCommon Stock | 10,600 | $30.54 | $323,724.00 |
DisclosureSEC source: 0001225208-13-022415 · doc4.xml · nonDerivative · entry 5 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,387,487 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2013. Read SEC document |
| October 28, 2013 Filed Oct 29, 2013 21:44 UTC |
READ IAN CDirector · Chairman & CEO
|
SaleCommon Stock | 6,700 | $30.58 | $204,886.00 |
DisclosureSEC source: 0001225208-13-022415 · doc4.xml · nonDerivative · entry 4 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,398,087 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2013. Read SEC document |
| October 28, 2013 Filed Oct 29, 2013 21:44 UTC |
READ IAN CDirector · Chairman & CEO
|
SaleCommon Stock | 5,680 | $30.53 | $173,410.40 |
DisclosureSEC source: 0001225208-13-022415 · doc4.xml · nonDerivative · entry 3 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,404,787 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2013. Read SEC document |
| October 28, 2013 Filed Oct 29, 2013 21:44 UTC |
READ IAN CDirector · Chairman & CEO
|
SaleCommon Stock | 1,800 | $30.57 | $55,026.00 |
DisclosureSEC source: 0001225208-13-022415 · doc4.xml · nonDerivative · entry 2 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,410,467 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2013. Read SEC document |
| October 28, 2013 Filed Oct 29, 2013 21:44 UTC |
READ IAN CDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 338,000 | $26.20 | $8,855,600.00 |
DisclosureSEC source: 0001225208-13-022415 · doc4.xml · nonDerivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,412,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2013 Filed Oct 16, 2013 19:02 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
GrantPhantom Stock Units SSP · Derivative | 74 | $29.16 | $2,157.84 |
DisclosureSEC source: 0001225208-13-021904 · doc4.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,115 Underlying: Common Stock · 74 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2013 Filed Oct 16, 2013 19:02 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantPhantom Stock Units SSP · Derivative | 46 | $29.16 | $1,341.36 |
DisclosureSEC source: 0001225208-13-021905 · doc4.xml · derivative · entry 1 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,518 Underlying: Common Stock · 46 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2013 Filed Oct 16, 2013 19:02 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 100 | $29.16 | $2,916.00 |
DisclosureSEC source: 0001225208-13-021906 · doc4.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,175 Underlying: Common Stock · 100 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2013 Filed Oct 16, 2013 19:02 UTC |
Dolsten MikaelPresident R&D
|
GrantPhantom Stock Units SSP · Derivative | 77 | $29.16 | $2,245.32 |
DisclosureSEC source: 0001225208-13-021907 · doc4.xml · derivative · entry 1 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,029 Underlying: Common Stock · 77 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2013 Filed Oct 16, 2013 19:02 UTC |
Germano Geno JBusiness Unit President
|
GrantPhantom Stock Units SSP · Derivative | 64 | $29.16 | $1,866.24 |
DisclosureSEC source: 0001225208-13-021908 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,094 Underlying: Common Stock · 64 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2013 Filed Oct 16, 2013 19:02 UTC |
HILL CHARLES HExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 47 | $29.16 | $1,370.52 |
DisclosureSEC source: 0001225208-13-021909 · doc4.xml · derivative · entry 1 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,489 Underlying: Common Stock · 47 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2013 Filed Oct 16, 2013 19:02 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 41 | $29.16 | $1,195.56 |
DisclosureSEC source: 0001225208-13-021910 · doc4.xml · derivative · entry 1 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,618 Underlying: Common Stock · 41 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2013 Filed Oct 16, 2013 19:02 UTC |
Lewis-Hall Freda CExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 63 | $29.16 | $1,837.08 |
DisclosureSEC source: 0001225208-13-021911 · doc4.xml · derivative · entry 1 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,424 Underlying: Common Stock · 63 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2013 Filed Oct 16, 2013 19:02 UTC |
MADDALUNA ANTHONY JExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 242 | $29.16 | $7,056.72 |
DisclosureSEC source: 0001225208-13-021912 · doc4.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,291 Underlying: Common Stock · 242 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2013 Filed Oct 16, 2013 19:02 UTC |
OLSON LAURIE JExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 35 | $29.16 | $1,020.60 |
DisclosureSEC source: 0001225208-13-021913 · doc4.xml · derivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 531 Underlying: Common Stock · 35 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2013 Filed Oct 16, 2013 19:02 UTC |
READ IAN CDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 343 | $29.16 | $10,001.88 |
DisclosureSEC source: 0001225208-13-021914 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,193 Underlying: Common Stock · 343 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2013 Filed Oct 16, 2013 19:02 UTC |
SCHULMAN AMY WExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 65 | $29.16 | $1,895.40 |
DisclosureSEC source: 0001225208-13-021915 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,750 Underlying: Common Stock · 65 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2013 Filed Oct 16, 2013 19:02 UTC |
SUSMAN SALLYExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 57 | $29.16 | $1,662.12 |
DisclosureSEC source: 0001225208-13-021916 · doc4.xml · derivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,863 Underlying: Common Stock · 57 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2013 Filed Oct 16, 2013 19:02 UTC |
YOUNG JOHN DBusiness Unit President
|
GrantPhantom Stock Units SSP · Derivative | 54 | $29.16 | $1,574.64 |
DisclosureSEC source: 0001225208-13-021917 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,862 Underlying: Common Stock · 54 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 30, 2013 Filed Oct 2, 2013 14:01 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
GrantPhantom Stock Units SSP · Derivative | 51 | $28.73 | $1,465.23 |
DisclosureSEC source: 0001225208-13-020973 · doc4.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,041 Underlying: Common Stock · 51 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 30, 2013 Filed Oct 2, 2013 14:01 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantPhantom Stock Units SSP · Derivative | 30 | $28.73 | $861.90 |
DisclosureSEC source: 0001225208-13-020974 · doc4.xml · derivative · entry 1 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,472 Underlying: Common Stock · 30 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 30, 2013 Filed Oct 2, 2013 14:01 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 58 | $28.73 | $1,666.34 |
DisclosureSEC source: 0001225208-13-020975 · doc4.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,075 Underlying: Common Stock · 58 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 30, 2013 Filed Oct 2, 2013 14:01 UTC |
Dolsten MikaelPresident R&D
|
GrantPhantom Stock Units SSP · Derivative | 72 | $28.73 | $2,068.56 |
DisclosureSEC source: 0001225208-13-020976 · doc4.xml · derivative · entry 1 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,952 Underlying: Common Stock · 72 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 30, 2013 Filed Oct 2, 2013 14:01 UTC |
Germano Geno JBusiness Unit President
|
GrantPhantom Stock Units SSP · Derivative | 54 | $28.73 | $1,551.42 |
DisclosureSEC source: 0001225208-13-020977 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,030 Underlying: Common Stock · 54 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 30, 2013 Filed Oct 2, 2013 14:01 UTC |
HILL CHARLES HExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 45 | $28.73 | $1,292.85 |
DisclosureSEC source: 0001225208-13-020978 · doc4.xml · derivative · entry 1 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,442 Underlying: Common Stock · 45 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 30, 2013 Filed Oct 2, 2013 14:01 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 37 | $28.73 | $1,063.01 |
DisclosureSEC source: 0001225208-13-020979 · doc4.xml · derivative · entry 1 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,577 Underlying: Common Stock · 37 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 30, 2013 Filed Oct 2, 2013 14:02 UTC |
Lewis-Hall Freda CExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 46 | $28.73 | $1,321.58 |
DisclosureSEC source: 0001225208-13-020980 · doc4.xml · derivative · entry 1 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,361 Underlying: Common Stock · 46 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 30, 2013 Filed Oct 2, 2013 14:02 UTC |
MADDALUNA ANTHONY JExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 196 | $28.73 | $5,631.08 |
DisclosureSEC source: 0001225208-13-020981 · doc4.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,049 Underlying: Common Stock · 196 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.